|2.||Non-Hodgkin Lymphoma (Lymphosarcoma)
|3.||Neoplasm Metastasis (Metastasis)
|4.||Breast Neoplasms (Breast Cancer)
|1.||Anderson, Kenneth C: 345 articles (12/2015 - 01/2002)|
|2.||Richardson, Paul G: 168 articles (01/2016 - 06/2002)|
|3.||Hideshima, Teru: 167 articles (10/2015 - 01/2002)|
|4.||Palumbo, Antonio: 142 articles (01/2016 - 06/2002)|
|5.||Chauhan, Dharminder: 113 articles (04/2014 - 02/2002)|
|6.||Munshi, Nikhil C: 111 articles (10/2015 - 02/2002)|
|7.||Rajkumar, S Vincent: 106 articles (09/2015 - 02/2002)|
|8.||Goldschmidt, Hartmut: 104 articles (11/2015 - 09/2002)|
|9.||Barlogie, Bart: 98 articles (12/2015 - 02/2002)|
|10.||Moreau, Philippe: 93 articles (01/2016 - 01/2002)|
|1.||bortezomib (Velcade)FDA Link
10/01/2007 - "In the Japanese phase I/II study of bortezomib for relapsed multiple myeloma, this agent showed remarkable efficacy, with acceptable toxicities and unique pharmacokinetic/pharmacodynamic profiles, warranting further investigations, including more relevant administration schedules."
04/01/2010 - "Bortezomib is highly effective in multiple myeloma and is widely used in this disease. "
01/01/2014 - "We have developed several other important use cases; as an example, we have shown that prediction of bortezomib sensitivity in multiple myeloma may be improved by training models on a large set of neoplastic hematological cell lines. "
01/01/2009 - "We here reported a case of rare MCD complicated with multiple myeloma who received bortezomib and achieved very good remission. "
08/01/2007 - "Multiple myeloma patients treated with bortezomib have gained a high overall response rate and complete remission rate. "
|2.||Thalidomide (Thalomid)FDA Link
01/01/2015 - "Thalidomide is highly effective against multiple myeloma, but some patients must discontinue this medication due to adverse effects. "
06/01/2004 - "Thalidomide has demonstrated a remarkable efficacy in the treatment of multiple myeloma but its use may cause several toxicities. "
01/01/2004 - "s-Thalidomide has proven efficacy in multiple myeloma. "
01/01/2003 - "Thalidomide is presently used in therapy of patients with resistant and relapsed multiple myeloma with very promising results."
01/01/2002 - "Thalidomide has recently proven to be a useful drug for treatment of refractory and relapsed multiple myeloma patients, up to 35% of whom achieve remission. "
|3.||Dexamethasone (Maxidex)FDA LinkGeneric
01/01/2016 - "Recent studies showed that CAM was highly effective against multiple myeloma (MM) when used in combination with immunomodulatory drugs and dexamethasone. "
01/01/1998 - "The authors describe a case of multiple myeloma in which a complete remission was obtained by treatment with high dose dexamethasone. "
10/01/2009 - "The high-dose dexamethasone-based regiments are safe and effective for newly diagnosed multiple myeloma patients with renal impairment."
02/01/1999 - "The use of biological modifiers in combination with dexamethasone offer a safe and effective therapeutic option in patients with refractory multiple myeloma. "
06/01/2015 - "In the present study, we conducted a subgroup analysis of the MM-021 registration trial to investigate the efficacy and safety of LEN plus low-dose dexamethasone (LoDEX) in Chinese patients with advanced relapsed or refractory multiple myeloma (RRMM) based on levels of RI. "
|4.||lenalidomide (CC 5013)FDA Link
06/01/2011 - "Also, the oral immunomodulator lenalidomide, first found to be active in advanced, relapsed multiple myeloma, was highly effective in intercepting the precursor stage, high-risk smoldering multiple myeloma from progressing. "
04/01/2010 - "Lenalidomide is an oral immunomodulatory drug that is highly effective in treating multiple myeloma, has a favorable safety profile and is now being evaluated as maintenance therapy, preventive therapy and in combination with other new agents."
02/01/2015 - "Finally, a further synergistically improved myeloma cell lysis with the daratumumab-IPH2102 combination was observed by adding lenalidomide, which suggests that more effective treatment strategies can be designed for multiple myeloma by combining daratumumab with agents that independently modulate natural killer cell function. "
11/01/2015 - "Lenalidomide is manageable and effective in multiple myeloma, particularly in elderly patients. "
09/01/2011 - "Lenalidomide is effective for extramedullary disease in relapsed or refractory multiple myeloma."
|5.||Proteasome Endopeptidase Complex (Proteasome)IBA
01/01/2015 - "Despite the fact that multiple myeloma (MM) is still an incurable disease, the outcome of patients who are eligible and ineligible for high-dose therapy has dramatically improved with the introduction of novel agents, that is proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs). "
01/01/2014 - "Inhibition of the proteasome has proven very effective in the treatment of multiple myeloma, and this approach is being tested for utility in other malignancies. "
01/01/2016 - "The development of proteasome inhibitors (PIs) and immunomodulatory drugs has significantly improved outcomes for patients with relapsed/refractory multiple myeloma (RRMM); however, not all patients benefit from treatment with these agents and some patients can become drug refractory over time. "
11/01/2015 - "Over the past decade, use of novel agents, including immunomodulatory drugs (IMiDs) and proteasome inhibitors (PIs) has resulted in high response rates and improvement in overall survival (OS) for patients with multiple myeloma (MM); however, the prognostic significance of refractoriness to these agents when used as initial therapy has not been extensively studied. "
10/01/2013 - "The outlook for patients with multiple myeloma (MM) has improved significantly with the development of new and more effective therapies, particularly the immunomodulatory agents and proteasome inhibitors. "
|6.||Melphalan (Alkeran)FDA LinkGeneric
01/01/1992 - "These results indicate that although VBAD is effective in at least one third of patients with advanced multiple myeloma resistant to melphalan, its impact on survival is limited."
03/01/1989 - "The response rate and the low toxicity observed in this group of patients are encouraging and suggest that intermediate-dose intravenous melphalan is an effective and safe second line treatment for patients with multiple myeloma not responding to conventional treatment."
06/01/2013 - "Here, we evaluated the efficacy of melphalan-flufenamide (mel-flufen), a novel dipeptide prodrug of melphalan in multiple myeloma. "
09/01/2010 - "200 mg/m(2) melphalan--the gold standard for multiple myeloma."
04/01/1996 - "Melphalan has brought the first improvement in the therapy of multiple myeloma at the beginning of the sixties. "
|7.||Cyclophosphamide (Cytoxan)FDA LinkGeneric
04/01/2001 - "High-dose cyclophosphamide (HDC) has been shown to be an effective regimen for collecting PBPC in multiple myeloma (MM) patients, but the optimal dose to be used remains controversial. "
08/01/1995 - "The aim of the study was to evaluate the feasibility and the efficacy of high-dose chemoradiotherapy followed by autologous hematopoietic stem cell support with peripheral blood progenitor cells (PBPC) harvested after high-dose cyclophosphamide (HDCYC) treatment in patients with high-risk multiple myeloma (MM). "
09/01/2013 - "These studies demonstrate that the pretransplantation exposure of multiple myeloma patients to novel immunomodulatory agents and cyclophosphamide significantly affects the subsequent risk of developing ES."
06/01/2007 - "To date, no systematic clinical study has investigated high-dose cyclophosphamide mobilization regimens in multiple myeloma patients and evaluated its cardiotoxicity. "
09/15/1999 - "The current study was designed to evaluate the effect of adding alternating cycles of IFN or early intensification with high dose cyclophosphamide (HiCy) to the VBMCP regimen for the treatment of multiple myeloma patients. "
|8.||Prednisone (Sone)FDA LinkGeneric
01/01/1994 - "The purposes of this study were (1) to estimate the response rate of alternate-day high dose prednisone in patients with relapsing and refractory multiple myeloma; (2) to measure the rate of GR levels; and (3) to correlate the response of prednisone with GR status. "
01/01/1975 - "A study was designed to evaluate the effectiveness of prednisone therapy in poor-risk patients with multiple myeloma. "
05/01/2002 - "Maintenance therapy with alternate-day prednisone improves survival in multiple myeloma patients."
01/01/1994 - "Alternate-day high-dose prednisone was well tolerated and may provide palliative benefit for a subset of patients with relapsing and refractory multiple myeloma. "
01/01/1994 - "Prednisone is an active drug in the treatment of multiple myeloma. "
|9.||Doxorubicin (Adriamycin)FDA LinkGeneric
10/01/2014 - "This study was aimed to investigate the molecular mechanism of doxorubicin resistance in multiple myeloma cell line and certify the effect of Notch signal over-expression on drug resistance of myeloma cells. "
12/01/2001 - "This study examined whether an Adriamycin-resistant multiple myeloma (MM) cell line (8226/Dox40) can be sensitized by Adriamycin (ADR) to Apo2L/TRAIL-mediated apoptosis. "
01/01/2015 - "We investigated the effect of autophagy on drug resistance of multiple myeloma (MM) to doxorubicin (DOX). "
01/01/2015 - "Autophagy in drug resistance of the multiple myeloma cell line RPMI8226 to doxorubicin."
10/01/2014 - "[Molecular mechanism of Doxorubicin resistance in multiple myeloma cell line]."
|10.||Vincristine (Oncovin)FDA LinkGeneric
01/01/2010 - "In this study, the effects of VAQuFrF extract were compared with those of vincristine in six human multiple myeloma cell lines (Molp-8, LP-1, RPMI-8226, OPM-2, Colo-677, and KMS-12-BM) using an in vitro model. "
11/01/1985 - "A phase 2 trial of vincristine infusion was conducted in a group of 21 patients with refractory multiple myeloma. "
06/30/1980 - "Effect of vincristine on the bone marrow cells of patients with multiple myeloma: a cytomorphologic study."
04/01/2015 - "Synergistic combination therapy with cotylenin A and vincristine in multiple myeloma models."
04/01/2015 - "Overexpression of survivin via activation of ERK1/2, Akt, and NF-κB plays a central role in vincristine resistance in multiple myeloma cells."
|1.||Drug Therapy (Chemotherapy)
12/01/2005 - "Clinical trials have shown that high dose chemotherapy (HDT) with peripheral stem cell autotransplantation is presently the best treatment for patients with symptomatic multiple myeloma (MM). "
04/01/2006 - "Multiple myeloma is the second most common haematological malignant disease, but cannot be cured with conventional and high-dose chemotherapy. "
12/01/2008 - "Multiple myeloma is an incurable clonal B-cell malignancy, which is initially responsive to conventional chemotherapy; one-third of the patients achieve complete remission but multidrug resistance eventually develops. "
07/01/2001 - "The introduction of high-dose treatment (HDT) with autologous hematopoietic stem cell support in patients with multiple myeloma (MM), although curative in only a minority of patients, has led to significantly longer event-free (EFS) and overall survival (OS) and likely improved quality of life compared with conventional chemotherapy. "
01/01/2001 - "Ten-year survivor with multiple myeloma in first complete remission following treatment with conventional chemotherapy. "
|2.||Stem Cell Transplantation
06/01/2015 - "High-dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) is the most common first-line treatment for patients with multiple myeloma (MM) under 65 years of age. "
10/01/2012 - "Autologous stem cell transplantation and novel therapies have improved overall survival of patients with multiple myeloma; however, most patients relapse and eventually succumb to their disease. "
12/01/2010 - "In 2000, the most important therapeutic improvement in multiple myeloma (MM) had been the introduction of high-dose therapy (HDT) supported by autologous stem cell transplantation, but this strategy was proposed only to younger patients without comorbidities. "
11/15/2008 - "Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation."
12/01/2007 - "Whether these early results will lead to prolonged overall survival and thereby ultimately redefine the role of stem cell transplantation in first-line treatment of multiple myeloma will be one of the most important questions to be answered in the coming years. "
10/01/2012 - "Despite the good response of stem cell transplant (SCT) in the treatment of multiple myeloma (MM), most patients relapse or do not achieve complete remission, suggesting that additional treatment is needed. "
01/01/2014 - "Autologous stem cell transplant (ASCT) is the standard of care in transplant-eligible multiple myeloma patients and is associated with significant improvement in progression-free survival (PFS), complete remission rates (CR), and overall survival (OS). "
02/01/2012 - "Complete response (CR) is associated with better outcome in patients with multiple myeloma (MM) treated with autologous transplant even though the progression-free survival (PFS) can be very variable among patients with good response. "
06/01/2010 - "Multiple myeloma suppression by Ax + radiation was accompanied by a marked decrease in the number and activity of osteoclasts in bone grafts assessed by histology. "
01/01/2003 - "Tandem transplants with different high-dose regimens improve the complete remission rates in multiple myeloma. "
|4.||Transplantation (Transplant Recipients)
10/01/2003 - "Autologous peripheral blood stem cell (PBSC) transplantation proved to increase complete remission (CR) and DFS in multiple myeloma (MM) patients. "
12/05/2014 - "There has been tremendous progress made in multiple myeloma in the last decade, resulting in improved overall survival for all patients, including those with high-risk disease and those ineligible for transplantation. "
03/01/2013 - "Impact of high-risk cytogenetics and achievement of molecular remission on long-term freedom from disease after autologous-allogeneic tandem transplantation in patients with multiple myeloma."
02/01/2005 - "Together with the rather good results in survival, the evaluation of quality of life invites further exploration of double transplantations in multiple myeloma."
12/01/2015 - "The overall survival of patients with multiple myeloma (MM) has been improved greatly over the last 2 decades with the broader use of novel drugs and autologous tandem transplantation. "
|5.||Combination Drug Therapy (Combination Chemotherapy)
09/01/1995 - "Our case indicated that one must include in the differential diagnosis of an osteosclerotic lesion the possibility of multiple myeloma, and that combination chemotherapy can induce a complete remission in this disease."
06/01/2008 - "Combination chemotherapy regimens have been developed providing high remission rates and remission quality in frontline treatment or in the relapsed setting in multiple myeloma. "
08/01/1993 - "Corticosteroid is not beneficial in multiple-drug combination chemotherapy for multiple myeloma. "
08/01/1986 - "Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest Oncology Group Study."
01/01/1998 - "[The efficacy of polychemotherapy programs in treating multiple myeloma patients]."